The LeenLife Pharma team has extensive experience in all facets of management, finance, marketing, operations and biotechnology.
Chief Executive Officer
Mr. Lis, was the co‐founder, past president and director of MicroCoal Technologies Inc. (formerly Carbon Friendly Solutions Inc.) since its inception in 2006 to 2015. From 2000 until 2006, he was the president, CEO and director of Stream Communications Network & Media Inc., a cable company where he was directly responsible for taking the company from start up to 65,000 subscribers. From 1993 until 2000, Mr. Lis acted as President, CEO and director of Trooper Technologies Inc., an environmental company focused on waste management in Central Europe. In 1988 he founded International UNP Holdings Ltd., a Toronto Stock Exchange Investment Company used to acquire and finance privatized Polish state enterprises. Mr. Lis studied Business Administration and Securities at the Simon Fraser University. Mr. Lis has personally raised over $60 million to finance the above mentioned companies.
Chief Financial Officer
Casey Forward, has been a CPA/CGA (professional accountant) in British Columbia since 1985. Mr. Forward has been a director, Chief Executive Officer and/or Chief Financial Officer of several public companies trading on the TSX and TSX Venture Stock Exchange in Canada. Most recently he was the CFO for NioCorp Development Ltd. from 2010 to 2015.
Engineer in agronomy, Academy of Agriculture, Wroclaw (Poland) (1990), MSc in Applied Natural Sciences (in French), University of Louvain‐la‐Neuve (Belgium) (1992). PhD (1992‐96) Laboratory
of Physiological Biochemistry, Catholic University of Louvain‐la Neuve (Belgium).
Since 2006 Head of Biotransformation Department, www.biotrans.uni.wroc.pl
2007‐2012 Dean Plenipotentiary for GMO
Since 2009 Rector Plenipotentiary for Nutribiomed Cluster in Wroclaw Technology Park
Since 2012 Dean of Faculty of Biotechnology of Wrocław University
Since 2014 Coordinator of KNOW consortium www.know.wroc.pl
Since 2014 Academic Editor of British Microbiology Research Journal.
Over 20 years of extensive business experience in all facets and levels of senior management, sales, finance and operations, in both the private and public sectors. Includes financial reporting, monthly, quarterly and annual budgets, staff mentoring, coaching and reviews, spearheading growth strategies, overseeing office administration, while achieving or exceeding company objectives and maintaining internal cost controls. Graduate of the CFP Education Program.
Elizabeth brings a unique corporate and legal perspective to LeenLife Pharma’s business and strategic planning. Elizabeth has over 20 years of legal and management experience. In December 2011 she founded and is currently Managing Director of LINK Business Law Group, a firm which addresses the business needs of companies by providing strategic and legal risk management advice as well as general counsel services.
From March 2008 to December 2011 she was Vice President and General Counsel of the Flora Group of Companies and was involved in all aspects of the company’s operations in addition to overseeing the company’s legal risk management processes and advising on a wide-range of legal and contractual issues. Flora manufactures and distributes premium natural health products and has distributorships in over 30 countries.
Elizabeth was called to the Bar of British Columbia in 1991 and practiced civil litigation at Basham Thompson & Liu LLP (now part of Owen Bird) where she also assumed the role of managing partner. Elizabeth has appeared as counsel in the Supreme Court of British Columbia, the BC Court of Appeal and the Federal Court of Canada on numerous occasions. While at Basham Thompson & Liu LLP, Elizabeth also created the Corporate Counsel Group (the precursor to LINK), a division that provided litigation reduction strategies and strategic planning advice to clients.
Elizabeth obtained her undergraduate degree from McGill University in 1987 and her law degree from the University of British Columbia in 1990.
Carl F. Perez, Ph.D.
Carl has a distinguished record of leadership in academic research programs and biologic & drug development.
More than 20 years of research-team supervision and leadership in the pharmaceutical industry, successfully combining diverse backgrounds, experience and temperaments.
Experienced in all phases of drug discovery, technology transfer, process development, biological assay development, preclinical development, manufacturing and clinical support.
Broad scientific background in cancer, immunology, and inflammation.
Prepared documents for FDA regulatory submissions: SOPs and technical reports, Type-II Drug Master File, and Biology Section for pre-IND package on humanized anti-VLA2 monoclonal antibody.
Engineered high-valued proteins for clinical development, including humanized monoclonal antibodies, selectins, cytokines, and enzymes for drug syntheses.
Ph.D. Biophysics University of California, Berkeley 1984
M.A. Bioradiology University of California, Berkeley 1979
A.B. Biophysics University of California, Berkeley 1976